Masquelet Induced-Membrane Technique

The Masquelet induced-membrane technique is a two-stage surgical strategy for reconstructing segmental bone defects, first described by Alain-Charles Masquelet in 1986. It exploits the body's foreign-body response to a block of polymethylmethacrylate (PMMA) cement to create a biologically privileged environment for bone grafting: the first stage grows the chamber, the second fills it.

The two stages. In the first stage, following radical debridement of nonviable bone and soft tissue, a PMMA cement spacer is inserted into the defect and the limb is stabilised. Over six to eight weeks a vascularised, bioactive "induced membrane" forms around the spacer. In the second stage the spacer is carefully removed while the membrane is preserved, and the cavity is filled with autologous cancellous bone graft, most commonly harvested from the iliac crest or by reamer-irrigator-aspirator (RIA) from the femoral canal.

Who. Candidates have critical-sized bone defects that will not heal spontaneously; the thresholds that define "critical" are set out under Pathology. The most common causes are high-energy open fractures (particularly Gustilo-Anderson type IIIB injuries), post-traumatic osteomyelitis, infected nonunion and defects created by tumour resection. The population skews toward young adult males, reflecting the demographics of high-energy trauma, though the technique is also applied in paediatric patients with congenital pseudarthrosis and in military casualties with blast injuries.

Where. The tibia is the most frequent site, where a precarious soft-tissue envelope and high rates of open fracture make segmental defects common. The femur is second, followed by the humerus and forearm and, less commonly, the hand, foot and clavicle. Defects ranging from 4 to 25 cm have been successfully reconstructed.

Why it matters. The technique is a technically accessible alternative to distraction osteogenesis (Ilizarov bone transport) and free vascularised fibular transfer, both of which demand prolonged treatment times or microsurgical expertise. Its principal virtues remain its simplicity, its reproducibility and its independence from a microsurgeon. The staged design accommodates infection control, because an antibiotic-laden cement spacer delivers high local antibiotic concentrations, which makes the technique especially valuable in septic nonunion.

What it delivers. Union rates of approximately 80 to 90% are reported in most series, even in defects exceeding 10 cm, although the tibia fares less well than the femur and the best pooled figure for a tibia is 84%. Complications, among them graft resorption, refracture, persistent infection and donor-site morbidity, are not rare. Success depends on adherence to the core principles: radical debridement, stable fixation, adequate soft-tissue coverage, atraumatic membrane preservation at the second stage, and grafting within the window of peak membrane bioactivity.

The problem. Segmental bone loss is one of the most challenging problems in orthopaedic reconstruction. It arises most commonly from high-energy open fractures, debridement of infected non-union, tumour resection and osteomyelitis. Left untreated, a critical defect progresses to atrophic non-union, deformity, chronic infection and, ultimately, limb-threatening dysfunction.

Two thresholds, often conflated. A critical-size defect, the point beyond which bone will not bridge on its own, is conventionally defined as a length over about 2 cm or loss of more than 50% of the cortical circumference; the regenerative capacity of bone is overwhelmed and the defect fills with fibrous tissue instead. That is a biological threshold, and it is convention rather than a measured cut-off. The practical threshold for choosing this operation is different and larger: most reported series reserve the induced-membrane technique for defects of roughly 2 to 5 cm and above, and the cohorts that define its results sit well beyond that, with 57% of Karger's defects exceeding 5 cm and Masquelet's original series spanning 4 to 25 cm.

What that means at the bedside. A 1.5 cm defect is critical-size but is usually managed by shortening, grafting or compression, not by a two-stage reconstruction. The workhorse role is the post-traumatic or post-infective long-bone defect, particularly of the tibia and femur, typically exceeding 4 to 5 cm, where acute shortening or conventional grafting would fail.

The membrane. The technique exploits the foreign-body reaction to the PMMA spacer. Rather than a nuisance, the fibrous capsule that forms, the induced membrane, is a biologically privileged structure that transforms a hostile defect into a favourable graft bed. It matures over 4 to 8 weeks and has three properties that matter:

• Richly vascularised, with a synovial-like epithelium on its inner surface; it behaves as a neo-periosteum, with an osteogenic surface layer facing the cement, and histologically it mimics true periosteal tissue
• Secretory, producing vascular endothelial growth factor (VEGF), transforming growth factor-beta (TGF-β1) and bone morphogenetic protein-2 (BMP-2), the osteoinductive and angiogenic factors that make it a biological chamber
• Containing, preventing graft resorption, soft-tissue interposition and fibrous ingrowth

The timing tension. The interval between stages is classically six to eight weeks, when the induced membrane is at its biological zenith. Pelissier's rabbit study is the source of all of this, and in it maximum BMP-2 production was at four weeks, at which point the membrane drove human bone marrow stromal cells toward the osteoblastic lineage; the authors themselves concluded that reconstruction "could be carried out earlier than previously thought". No human trial has settled the interval.

View larger

View larger

Relevant anatomy. Defects most frequently involve the tibia, femur and forearm, and each brings its own constraint:

The blood supply. The periosteal and endosteal blood supply must be respected during debridement. The nutrient artery is frequently compromised, and healing then depends on periosteal and membrane-derived vascularity.

The stories. A patient presenting for consideration of induced-membrane reconstruction usually offers one of four narratives:

• High-energy open fracture (Gustilo IIIB/IIIC), often with segmental bone loss at the time of injury or following serial debridement
• Chronic osteomyelitis requiring segmental resection of infected, sequestrated bone
• Infected non-union, frequently after multiple failed fixation attempts
• Tumour resection, occasionally, where biological reconstruction is preferred over endoprosthesis

The history. Document previous operations, antibiotic courses, smoking status, diabetes and nutritional state. All of them prejudice membrane quality and graft incorporation.

Examination. What you find depends on where the patient is in the pathway:

View larger

What it can be confused with. The induced membrane itself, and the clinical picture surrounding the technique, may be mistaken for several other entities:

• Periosteum, which the membrane mimics in structure and behaviour
• Infected collection or abscess: at second-stage surgery the fluid surrounding the spacer can resemble pus; culture and inspection are mandatory before proceeding to graft
• Foreign-body granuloma: histological appearances overlap, since the membrane is fundamentally a foreign-body reaction to PMMA
• Persistent non-union: slow graft incorporation on radiographs may be misread as failure; consolidation frequently requires up to a year

Success of the second stage depends on rigorous assessment before the cement spacer is exchanged. The surgeon must be satisfied on two counts, that infection is controlled and that the membrane is biologically competent, and imaging, blood tests and tissue each answer part of that. The technique forgives many sins, but not sepsis.

Radiographs. Plain radiography remains the first-line investigation between stages. Assess:

• Position and integrity of the PMMA spacer, which should overlap the bone ends so that membrane is induced over viable cortex
• Stability of fixation, with no lucency around implants
• Evidence of persistent sequestrum, periosteal reaction or progressive osteolysis suggesting ongoing sepsis

View larger

View larger

CT. CT gives superior delineation of defect geometry, occult sequestra and the quality of the bone ends. Measure defect length on orthogonal reconstructions: defects exceeding 5 cm traditionally favour induced-membrane reconstruction over acute shortening, and the upper limits at which the alternatives enter the discussion are set out under Management.

View larger

MRI. Valuable where residual osteomyelitis is suspected. It shows marrow oedema (low T1, high STIR signal), the classic penumbra sign of intraosseous abscess, a thin T1-hyperintense rim around a low-signal collection, and sinus tracts. Metal artefact reduction sequences are advisable in the presence of fixation.

Nuclear imaging. Labelled leucocyte scintigraphy or FDG-PET/CT is reserved for equivocal cases, where its high negative predictive value helps exclude persistent infection.

Blood tests. Serial inflammatory markers should be trending towards normal before second-stage grafting:

Vitamin D deficiency should be corrected, and smoking cessation strongly encouraged, given their deleterious effect on graft incorporation.

Tissue, not serology. Definitive exclusion of infection rests on tissue sampling, and the principles mirror those established for prosthetic joint infection:

• Withhold antibiotics for at least two weeks before sampling where clinically safe
• Take a minimum of five deep tissue samples from representative sites (membrane, bone ends, medullary canal), each with clean, unused instruments
• Send specimens for extended-culture microbiology (including fungal and mycobacterial culture where indicated) and histopathology; more than five neutrophils per high-power field suggests active infection
• Sonication of removed spacers or implants improves organism yield in biofilm-associated infection
• Molecular techniques (16S rRNA PCR) may assist in culture-negative cases

Only when imaging, biochemistry and tissue diagnostics are concordant should the surgeon proceed to membrane preservation and autologous grafting.

Start with the defect and the limb. Measure the segmental bone loss after the planned debridement margins, and assess the soft-tissue envelope and limb perfusion; document sensation, vascularity and physiological reserve. Not every defect demands reconstruction, and conservative management or simpler measures are appropriate when:

• The defect is under 2 cm with a stable, well-vascularised envelope, where acute shortening or conventional grafting often suffices
• The limb is insensate or dysvascular, or the patient's physiological reserve is poor, where amputation may serve better
• Active, undrained infection persists, because reconstruction before source control invites failure
• The patient cannot tolerate or comply with a prolonged, staged pathway

Indications. Segmental defects of 2 to 25 cm, typically post-traumatic, post-infective (following excision of infected non-union or osteomyelitis) or post-tumour resection, and composite injuries where soft-tissue reconstruction can be staged alongside the first stage.

Choosing between reconstructions. Three options compete for the same defect, and they differ in the size they suit, how they handle infection and what they demand of surgeon and patient.

The induced membrane is favoured by a defect of 2 to 25 cm, typically under 15 cm, with controlled infection, a healthy or flap-reconstructable soft-tissue envelope, adequate autograft supply from iliac crest or RIA, and a patient who can complete two stages 6 to 8 weeks apart. Transport or a vascularised fibula is favoured by a defect greater than 15 to 20 cm or a failed Masquelet, insufficient autograft volume for the chamber, recurrent infection despite spacer exchange, a need for concurrent limb lengthening or deformity correction, and available microvascular expertise with an acceptable donor fibula. At that size, or after a failed Masquelet, hybrid techniques sit alongside vascularised fibular transfer and bone transport as the options to consider, and beyond 10 to 15 cm those alternatives may already prompt consideration.

Read the length thresholds against the evidence. Karger, Hsu and Griffin all found that defect length does not itself predict failure to unite. In Hsu's analysis a defect of 7 cm or more and a pre-existing infected nonunion each raised post-operative infection, and infection lowered union, so length acts through infection. A 15 cm defect is not a reason to abandon the technique on length alone; it is a reason to put the whole effort into source control, and in that analysis an antibiotic-loaded spacer significantly reduced the need for revision.

Stage one. Debridement is the foundation of the operation, and everything after it depends on its being radical: inadequate debridement leaves a septic bed that dooms the reconstruction. The sequence:

1. Radical debridement of all necrotic and infected bone until punctate bleeding, the "paprika sign"; send deep tissue for culture and histology
2. Stabilisation with internal fixation (plate or nail) where infection is controlled, or external fixation if contamination is high
3. Spacer insertion: PMMA cement, antibiotic-loaded where infection is suspected, moulded to fill the defect and overlap both bone ends, ideally by 1 to 2 cm
4. Soft-tissue cover with a flap at the same sitting or within days; a healthy envelope is non-negotiable, and where the soft tissues are inadequate, flap coverage takes priority before proceeding

The interval. Over the following six weeks the membrane forms around the spacer, and the window is used to optimise the host: stop smoking, control diabetes and correct nutrition, all of them modifiable determinants of union. Positive cultures from stage one mean tailored antibiotics, delay of stage two, and consideration of repeat debridement with spacer exchange.

Stage two, typically 6 to 8 weeks later. The membrane is the biological chamber, and the operation is built around not damaging it:

1. Incise the membrane longitudinally with care and preserve it
2. Remove the spacer piecemeal, without damaging the membrane
3. Freshen and reopen the medullary canals of both bone ends
4. Fill the chamber with morcellised autologous cancellous graft from the iliac crest or RIA harvest, diluting with allograft or substitutes only if volume exceeds supply, ideally at no more than a 1:3 ratio
5. Close the membrane over the graft, avoiding over-compaction, which impairs revascularisation

When to stop. If the membrane is violated, or purulence or recurrent infection is found at stage two, abandon grafting, re-debride and insert a new spacer; the maturation interval restarts before stage two is attempted again.

The technique carries a recognised complication profile across both stages. Reported failure rates requiring further intervention range from 10 to 50%, reflecting heterogeneity in defect aetiology, host physiology and technical execution, and failure is most often attributable to inadequate initial debridement or persistent infection rather than to graft biology. The six principal modes of failure are set out below, each with its prevention and its salvage:

When salvage fails. Refractory cases may warrant conversion to bone transport, vascularised fibular grafting or, rarely in the lower limb, amputation following candid shared decision-making. In the SoFCOT series of 84, six of the eight failures required amputation, all severe leg injuries combining extensive defect, soft-tissue loss and infection; amputation remains a real endpoint in the long infected defect and must be named at consent.

Prognosis. The union rates quoted under Overview apply to appropriately selected patients, and even then 40 to 50% may require an additional procedure. Time to union is typically 6 to 12 months, though in the SoFCOT series the mean was 14.4 months from the first stage, reached after a mean of 6.11 interventions, with malalignment in 17% and delayed corrective surgery, mostly to the foot, in a further 16%. Adverse prognostic factors are smoking, diabetes mellitus, defects greater than 8 cm, prior infection and poor soft-tissue coverage, and smoking cessation should be considered near-mandatory before the second stage. Patients must be counselled that consolidation is measured in months, about the possibility of repeat grafting and donor-site morbidity, and that consent is for well over a year of treatment, not for an operation and a recovery.

Surveillance. Follow-up continues for a minimum of two years:

• Clinical review at 6-weekly intervals initially, assessing pain, wound status and weight-bearing progression, with protected weight-bearing advanced as consolidation appears
• Serial radiographs to monitor graft incorporation and corticalisation, with CT where union is equivocal
• Inflammatory markers (CRP, ESR) if infection is suspected
• Vigilance for late stress fracture until full cortical remodelling is evident

The Masquelet Induced-Membrane Technique: Global Variation in Practice

Overview

The induced-membrane technique, described by Alain-Charles Masquelet in 1986, remains a mainstay for segmental bone defect reconstruction. Its two-stage design—cement spacer insertion with membrane induction, followed by autologous grafting at six to eight weeks—is conceptually simple, yet worldwide practice is remarkably heterogeneous. The consultant should appreciate that much of what we "know" derives from case series rather than robust comparative evidence.

Variation in Practice

Practice differs at almost every decisional node:

• Spacer composition: Plain polymethylmethacrylate (PMMA) versus antibiotic-loaded cement. Most units add gentamicin or vancomycin empirically, though Masquelet's original description used plain cement, and laboratory data suggest antibiotic loading has little effect on membrane biology.
• Interval timing: The classical 6–8 week interval is honoured more in the breach; series report second stages from 4 weeks to over 6 months, particularly where infection eradication must be confirmed.
• Graft material: Iliac crest autograft remains the reference standard, but Reamer–Irrigator–Aspirator (RIA) harvest predominates in North America and much of Europe. Extenders—allograft, tricalcium phosphate, demineralised bone matrix—are commonly added when defect volume exceeds harvestable autograft, typically in ratios up to 1:3.
• Fixation: External fixation, plating, and intramedullary nailing are all reported; nail-plus-membrane constructs are increasingly favoured for femoral and tibial defects in well-resourced settings.

Resource-Setting Considerations

In low- and middle-income countries, the technique's appeal lies precisely in avoiding microsurgical expertise and specialised frames. Series from sub-Saharan Africa and South Asia report acceptable union rates despite delayed presentation and higher infection burdens, though follow-up attrition limits interpretation.

Guideline and Registry Evidence

Here candour is required: no national or international guideline mandates a specific Masquelet protocol, and no dedicated registry exists. The evidence base comprises:

• Systematic reviews (e.g. Morelli et al., 2016) pooling heterogeneous case series, reporting union rates of roughly 80–90% but with wide confidence intervals.
• The French Society of Orthopaedic Surgery (SoFCOT) symposium data, the nearest approximation to multicentre registry evidence, describing outcomes across French centres.
• No randomised trial has directly compared induced-membrane reconstruction with distraction osteogenesis; retrospective comparisons suggest broadly equivalent union with differing complication profiles.

Summary

The Masquelet technique exemplifies a procedure diffused globally ahead of its evidence. The prudent consultant adheres to sound principles—radical debridement, stable fixation, membrane preservation at second stage—while acknowledging that spacer additives, interval timing and graft augmentation remain matters of institutional custom rather than proven doctrine.

Related pages. The alternatives for the same defect: Bone Transport Techniques and Distraction Osteogenesis with Ilizarov External Fixation and Hexapod Frame Deformity Correction, and Free Vascularised Fibula Transfer where a vascularised strut is preferred.